GKOS vs. HAE, STVN, MMSI, INSP, AXNX, PRCT, IRTC, PEN, TNDM, and GMED
Should you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include Haemonetics (HAE), Stevanato Group (STVN), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), Axonics (AXNX), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), Penumbra (PEN), Tandem Diabetes Care (TNDM), and Globus Medical (GMED). These companies are all part of the "surgical & medical instruments" industry.
Haemonetics (NYSE:HAE) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
Haemonetics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.
Haemonetics has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
Haemonetics has a net margin of 8.98% compared to Haemonetics' net margin of -43.15%. Glaukos' return on equity of 22.25% beat Haemonetics' return on equity.
Glaukos received 41 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 64.54% of users gave Glaukos an outperform vote while only 60.89% of users gave Haemonetics an outperform vote.
In the previous week, Haemonetics had 5 more articles in the media than Glaukos. MarketBeat recorded 19 mentions for Haemonetics and 14 mentions for Glaukos. Haemonetics' average media sentiment score of 0.53 beat Glaukos' score of 0.51 indicating that Glaukos is being referred to more favorably in the news media.
99.7% of Haemonetics shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 1.8% of Haemonetics shares are held by company insiders. Comparatively, 6.4% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Haemonetics presently has a consensus target price of $108.67, indicating a potential upside of 13.51%. Glaukos has a consensus target price of $108.64, indicating a potential downside of 1.05%. Given Glaukos' higher possible upside, equities research analysts clearly believe Haemonetics is more favorable than Glaukos.
Summary
Haemonetics beats Glaukos on 10 of the 18 factors compared between the two stocks.
Get Glaukos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
